Vancouver, BC – GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace. Precision prescribing has become a leading method to bring pharmacogenetics (PGx) closer to the standard of care for certain…
All TreatGx users now have access to the updated treatment algorithms for Post-Myocardial Infarction and Osteoporosis. As always, these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. Post-Myocardial Infarction This update includes recommendations from…
Top Five Questions and Answers from Canada’s ‘Godfather’ of Life Sciences, Dr. Pieter Cullis You’ve been on the cutting edge of life sciences for many years in taking the ‘lab to the bedside’ to improve health – can you tell us…
All TreatGx users now have access to the updated treatment algorithm for Diabetes Mellitus Type 2. Diabetes Mellitus Type 2 This comprehensive update accounts for revisions made to existing clinical guidelines that will help health care providers select the safest and most effective medications with their…
Earlier this year, I decided to take the plunge and join the board of GenXys Health Care Systems (GenXys) as an independent board member. I have been intrigued by precision medicine for years, wondering why this has been historically slow to…
Vancouver, BC – GenXys Health Care Systems (GenXys), the award-winning precision prescribing company, today announced a partnership with Helix, a leading population genomics company working at the intersection of clinical care, research, and genomics. Together, the companies will be working to…
Katie Capps from GTMRx Institute was a guest on our podcast, Precision Insights, and gave listeners an overview on what comprehensive medication management (CMM) is, and how pharmacogenetics can become part of that process. We’ve taken some of the highlights of this episode and put them here for your reading pleasure.
All TreatGx users now have access to the updated treatment algorithms for Hypertension and Migraine. As always, these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. General updates: a scope…
At the time of recording, Colleen Keenan was a consultant with Advisory Board’s Clinical Innovators Council, a membership group for researchers designed to help suppliers strengthen their relationships with integrated delivery networks and their providers. Colleen had been with Advisory Board for over four years and has worked in several areas, including pharmacy and devices. She recently left Advisory Board to pursue graduate studies.
GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada, (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).